Page 20 - CIBERES2016-ENG

• WP8-Other pathogens causing CAP. Txema Marimón
• WP9-Dissemination. Antoni Artigas
The “Pneumocoper” programme made satisfactory progress in most of the 9 sub-programmes in 2016, with the publication of diverse articles in the first decile and quartile, doctoral theses, official and unofficial research projects, clinical guides and interaction with private companies.
Diffuse Respiratory Disease Programme
Coordinator: Francisco Pérez Vizcaíno
Lines:
ACUTE lUNg INjURy (AlI) PUlMONARy FIBROSIS (PF) PUlMONARy hyPERTENSION (Ph)
CLINICAL GUIDES
• European and Spanish clinical guides on the diagnosis and treatment of PH.
• Redefinition of the Acute Respiratory Distress Syndrome (ARDS).
GENETICS
• Genome analysis (GWAS) of patients at risk of ARDS. Development of the PH biobank.
• Participation in the International PAH Genetics Consortium.
GENOMIC, TRANSCRIPTOMIC AND METABOLOMIC BIOMARKERS
• Profile of expression of angiogenic factors in vascular remodelling in COPD.
• Metabolomic characterisation in PH and ARDS.
• Changes in microparticles, microRNAs and endothelium progenitor cells circulating in arterial and
thromboembolic PH.
EPIDEMIOLOGY
• Strategies for ventilation and prognosis of patients at risk of ARDS.
• Therapeutic handling and prognosis of patients with chronic thromboembolic PH.
• Predictive and prognostic factors of telomere shortening in PF.
IMAGING
• Utility of (68) Ga-DOTA PET for measuring regional pulmonary blood flow.
• Development of microCT, microCT-PET, microCT-SPECT to evaluate pulmonary structure, inflammation
and vascular remodelling.
• In vivo imaging with new biocompatible systems of metallic nanoparticles.
• Marking of autologous erythrocytes with 18F-FDF.
PHYSIOPATHOLOGY
• The role of angiopoietin-2 in PH associated with COPD.
• Acid sphingomyelinase and IL-6 in endotoxin-induced vascular dysfunction.
• Role of Slug in vascular proliferation and remodelling.
12203